Company intelligence / Profile preview

Enterologics, Inc.

Saint Paul, Minnesota, United States

Ownership: Private
Development stage: Other

Overview

E. coli M17 (Probactrix®) has an active IND for chronic pouchitis as maintenance therapy alternative to antibiotics; no clinical trial results reported.

Therapeutic areas: Infectious DiseasesGastroenterology
Modalities: Live biotherapeutic product therapy
Industry: Biotech

Partnerships

Universal Stabilization Technologies

Beyond the preview

Go deeper on Enterologics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enterologics, Inc..

Explore the full profile